DUBLIN, Ohio--(BUSINESS WIRE)--Jan. 6, 2017--
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that
management will present at an upcoming investor conference. An audio
webcast of the presentation will be available live at the URL links
noted below. An archived version of the webcast will be available
approximately two hours following the presentations and can be accessed
within the Investors' section of the Navidea website http://ir.navidea.com.
2017 Biotech Showcase Conference in San Francisco on
Monday, January 9, 2017 at 4:30 p.m., Pacific Time (7:30 p.m. ET).
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1131242
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products and platforms including Manocept™
and NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical decision-making,
targeted treatment and, ultimately, patient care. Lymphoseek®
(technetium Tc 99m tilmanocept) injection, Navidea’s first commercial
product from the Manocept platform, was approved by the FDA in March
2013 and in Europe in November 2014. The development activities of the
Manocept immunotherapeutic platform will be conducted by Navidea in
conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel products and advancing the Company’s pipeline
through global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170106005718/en/
Source: Navidea Biopharmaceuticals, Inc.
Investors & Media
COO & CFO